Advertisement

Cancer Immunology, Immunotherapy

, Volume 59, Issue 5, pp 799–803 | Cite as

Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3

  • Cornelia L. TrimbleEmail author
  • Shiwen Peng
  • Christopher Thoburn
  • Ferdynand Kos
  • T. C. Wu
Short Communication

Abstract

Essentially all squamous cervical cancers and their precursor lesions, high grade cervical intraepithelial neoplasia (CIN2/3), are caused by persistent human papillomavirus (HPV) infection. However, not all CIN2/3 lesions progress to cancer. In a brief, observational study window monitoring subjects with CIN2/3 from protocol entry (biopsy diagnosis) to definitive therapy (cervical conization) at week 15, in a cohort of 50 subjects, we found that 26% of CIN2/3 lesions associated with HPV16, the genotype most commonly associated with disease, underwent complete histologic regression. Nonetheless, HPV16-specific T cell responses measured in peripheral blood obtained at the time of study entry and at the time of conization were marginally detectable directly ex vivo, and did not correlate with lesion regression. This finding suggests that, in the setting of natural infection, immune responses which are involved in elimination of cervical dysplastic epithelium are not represented to any great extent in the systemic circulation.

Keywords

Human papillomavirus (HPV) Cervical dysplasia Regression Systemic immune response 

Abbreviations

HPV

Human papillomavirus

CIN

Cervical intraepithelial neoplasia

SCC

Squamous cervical cancer

PBMC

Peripheral blood mononuclear cells

ELISPOT

Enzyme-linked immunosorbent spot assay

Notes

Acknowledgments

This work was supported by the National Institutes of Health (P50 CA098252) and by the Dana Foundation (CLT).

References

  1. 1.
    Frazer IH, Lowy DR, Schiller JT (2007) Prevention of cancer through immunization: prospects and challenges for the 21st century. Eur J Immunol 37(Suppl 1):S148–S155CrossRefPubMedGoogle Scholar
  2. 2.
    Bosch F et al (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87:796–802CrossRefPubMedGoogle Scholar
  3. 3.
    Hudson J et al (1990) Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J Virol 64:519–526PubMedGoogle Scholar
  4. 4.
    Werness B, Levine A, Howley P (1990) Association of human papillomavirus types 16 and 18 proteins with p53. Science 248:76–79CrossRefPubMedGoogle Scholar
  5. 5.
    Melnikow J et al (1998) Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 92(4 Pt 2):727–735CrossRefPubMedGoogle Scholar
  6. 6.
    Trimble CL et al (2005) Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res 11(13):4717–4723CrossRefPubMedGoogle Scholar
  7. 7.
    Schlecht NF et al (2003) Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 95(17):1336–1343PubMedGoogle Scholar
  8. 8.
    Kanodia S, Da Silva DM, Kast WM (2008) Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer 122(2):247–259CrossRefPubMedGoogle Scholar
  9. 9.
    Currier JR et al (2002) A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 260(1–2):157–172CrossRefPubMedGoogle Scholar
  10. 10.
    Gravitt PE (2003) Reproducibility of HPV16 and HPV18 viral load quantitation using TaqMan real-time PCR assays. J Virol Methods 112(1–2):23–33CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Cornelia L. Trimble
    • 1
    Email author
  • Shiwen Peng
    • 3
  • Christopher Thoburn
    • 2
  • Ferdynand Kos
    • 2
  • T. C. Wu
    • 3
  1. 1.Department of Gynecology and ObstetricsJohns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Department of OncologyJohns Hopkins University School of MedicineBaltimoreUSA
  3. 3.Department of PathologyJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations